TR199902033T2 - Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari. - Google Patents

Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari.

Info

Publication number
TR199902033T2
TR199902033T2 TR1999/02033T TR9902033T TR199902033T2 TR 199902033 T2 TR199902033 T2 TR 199902033T2 TR 1999/02033 T TR1999/02033 T TR 1999/02033T TR 9902033 T TR9902033 T TR 9902033T TR 199902033 T2 TR199902033 T2 TR 199902033T2
Authority
TR
Turkey
Prior art keywords
glitazone
diabetes
sulfonylura
synergistic combinations
antidiabetic agent
Prior art date
Application number
TR1999/02033T
Other languages
English (en)
Inventor
W. Whitcomb Randall
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR199902033T2 publication Critical patent/TR199902033T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus, diyabetin tedaviye ihtiyaç duyan hastaya bir sülfonilurea antidiyabetik madde ile bir glitazon antidiyabetik maddenin bir kombinasyonunun verilmesiyle tedavisi için bir yöntem saglanmaktadir.
TR1999/02033T 1997-02-19 1997-12-01 Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari. TR199902033T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19

Publications (1)

Publication Number Publication Date
TR199902033T2 true TR199902033T2 (tr) 2000-02-21

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02033T TR199902033T2 (tr) 1997-02-19 1997-12-01 Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari.

Country Status (29)

Country Link
US (2) US5859037A (tr)
EP (1) EP0957923A1 (tr)
JP (1) JP2001512478A (tr)
KR (1) KR20000071179A (tr)
CN (1) CN1244801A (tr)
AR (1) AR011829A1 (tr)
AU (1) AU741215B2 (tr)
BG (1) BG103671A (tr)
BR (1) BR9714505A (tr)
CA (1) CA2272478A1 (tr)
CZ (1) CZ289299A3 (tr)
EA (1) EA199900725A1 (tr)
EE (1) EE9900345A (tr)
GT (1) GT199800037A (tr)
HN (1) HN1997000167A (tr)
HU (1) HUP0001528A3 (tr)
IL (1) IL130027A (tr)
IS (1) IS5058A (tr)
NO (1) NO993982D0 (tr)
NZ (1) NZ336002A (tr)
PA (1) PA8447401A1 (tr)
PE (1) PE74399A1 (tr)
PL (1) PL335166A1 (tr)
SK (1) SK111899A3 (tr)
SV (1) SV1998000010A (tr)
TR (1) TR199902033T2 (tr)
UY (1) UY24893A1 (tr)
WO (1) WO1998036755A1 (tr)
ZA (1) ZA981343B (tr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
CA2294385C (en) * 1997-06-18 2007-06-05 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
SK9172001A3 (en) * 1998-12-24 2002-04-04 Metabasis Therapeutics Inc A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
AU784108B2 (en) * 1999-03-15 2006-02-02 University Of British Columbia, The Methods and reagents for modulating cholesterol levels
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
EP1145717B1 (en) * 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP1539144B1 (en) 2002-09-20 2014-12-24 Andrx Labs Llc Multistage formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
RU2359661C2 (ru) 2003-10-31 2009-06-27 Такеда Фармасьютикал Компани Лимитед Твердый препарат
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
WO2006126673A1 (ja) * 2005-05-27 2006-11-30 Daiichi Sankyo Company, Limited 組み合わせによる糖尿病治療薬
EP1943274A2 (en) * 2005-09-08 2008-07-16 Uutech Limited Treatment of diabetes related obesity
US20090286722A1 (en) * 2005-09-08 2009-11-19 Utech Limited Analogs of Gastric Inhibitory Polypeptide as a Treatment for Age Related Decreased Pancreatic Beta Cell Function
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
AR058605A1 (es) 2005-12-22 2008-02-13 Takeda Pharmaceutical Preparacion solida
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
KR101808787B1 (ko) 2007-03-30 2017-12-13 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
ES2638977T3 (es) 2007-12-04 2017-10-24 Biogen Chesapeake Llc Formulaciones y procedimientos mejorados para liofilización y liofilizados obtenidos por los mismos
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
KR101946297B1 (ko) * 2008-12-04 2019-02-11 충시 위 고투과력을 가진 조성물 및 이의 적용
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
WO2011059053A1 (ja) * 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
AU2011257964B2 (en) * 2010-05-24 2014-10-30 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions and methods
EP4282363A3 (en) 2011-01-19 2024-01-10 Fractyl Health, Inc. Devices for the treatment of tissue
CN104244958B (zh) 2011-11-23 2017-11-17 澳星医疗私人有限公司 改进的协同抗糖尿病组合物
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
EP4066764A1 (en) 2012-02-27 2022-10-05 Fractyl Health, Inc. Heat ablation systems and devices for the treatment of tissue
WO2015077571A1 (en) 2013-11-22 2015-05-28 Fractyl Laboratories, Inc. Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
EP3711810B1 (en) 2012-04-19 2023-02-22 Fractyl Health, Inc. Tissue expansion systems
EP3714826A1 (en) 2012-07-30 2020-09-30 Fractyl Laboratories, Inc. Electrical energy ablation systems and devices for the treatment of tissue
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
WO2014055997A1 (en) 2012-10-05 2014-04-10 Fractyl Laboratories Inc. Methods, systems and devices for performing multiple treatments on a patient
EP3003461B1 (en) 2013-06-04 2019-05-01 Fractyl Laboratories, Inc. Systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2015038973A1 (en) 2013-09-12 2015-03-19 Fractyl Laboratories, Inc. Systems, methods and devices for treatment of target tissue
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US9844641B2 (en) 2014-07-16 2017-12-19 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
EP3169260B1 (en) 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
CN114853868A (zh) 2014-10-24 2022-08-05 百时美施贵宝公司 修饰的fgf-21多肽及其用途
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
HUP9601808A3 (en) * 1995-07-03 2000-06-28 Sankyo Co Treatment of arteriosclerosis and xanthoma
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
BG103671A (en) 2000-04-28
PE74399A1 (es) 1999-08-20
NO993982L (no) 1999-08-18
SV1998000010A (es) 1999-02-02
AR011829A1 (es) 2000-09-13
AU5590898A (en) 1998-09-09
ZA981343B (en) 1998-11-16
KR20000071179A (ko) 2000-11-25
IL130027A0 (en) 2000-02-29
CZ289299A3 (cs) 1999-11-17
JP2001512478A (ja) 2001-08-21
BR9714505A (pt) 2000-03-21
AU741215B2 (en) 2001-11-29
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
NO993982D0 (no) 1999-08-18
NZ336002A (en) 2002-03-28
CA2272478A1 (en) 1998-08-27
US5859037A (en) 1999-01-12
HN1997000167A (es) 1999-02-09
PL335166A1 (en) 2000-04-10
HUP0001528A3 (en) 2000-12-28
IS5058A (is) 1999-05-27
WO1998036755A1 (en) 1998-08-27
CN1244801A (zh) 2000-02-16
UY24893A1 (es) 1998-07-10
IL130027A (en) 2005-09-25
EE9900345A (et) 2000-02-15
PA8447401A1 (es) 2001-12-14
EP0957923A1 (en) 1999-11-24
US5972973A (en) 1999-10-26
EA199900725A1 (ru) 2000-04-24
SK111899A3 (en) 2000-09-12

Similar Documents

Publication Publication Date Title
TR199902033T2 (tr) Diyabet için sülfonilura-glitazon sinerjik kombinasyonlari.
DK0987998T3 (da) Decellulering af væv
MX9101913A (es) Derivados de quinazolinas para potenciar la actividad antitumoral
GB9818916D0 (en) Use
ATE324119T1 (de) Verwendung von saccharid-konjugaten
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
TR200101174T2 (tr) Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid.
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
DE69012124D1 (de) Verbesserungen bei der behandlung von zähnen.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
ES2184800T3 (es) Uso de agentes anti-vegf en el tratamiento de la endometriosis.
PT1052905E (pt) Processo anti-germinativo de tuberculos e bolbos utilizando o eugenol e/ou o isoeugenol
TR200000662T2 (tr) Doğal-olmayan seçici agonistler kullanılarak kemik hacminin arttırılması yöntemi.
GR1002802B (el) Καλλυντικες συνθεσεις και συνθεσεις περιποιησεως του δερματος
BR9808221A (pt) Método de tratamento de tumor.
TR200000134T2 (tr) Tiazolidinedion, ensülin salgılatıcısı ve biguanid ile diabetin (şeker hastalığının) tedavisi.
TR200000135T2 (tr) Tiazolidinedion ve sülfonilüre ile diabet tedavisi.
BR9915214A (pt) Combinações contendo um beta-agonista e umagente anti-diabético adicional
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
NZ514691A (en) Method to type prion proteins
NO970607D0 (no) Anordning av selegilin i behandling av epileptiske tilstander
ZA981558B (en) Inclusion complexes in aqueous solution
ATE364180T1 (de) Screeningverfahren mit bnpi und dnpi
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.